A detailed history of High Tower Advisors, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 7,982 shares of VKTX stock, worth $419,773. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,982
Previous 4,735 68.57%
Holding current value
$419,773
Previous $251,000 101.2%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $161,830 - $228,816
3,247 Added 68.57%
7,982 $505,000
Q2 2024

Aug 13, 2024

SELL
$47.39 - $80.2 $18,150 - $30,716
-383 Reduced 7.48%
4,735 $251,000
Q1 2024

May 06, 2024

BUY
$17.4 - $94.5 $89,053 - $483,651
5,118 New
5,118 $419,000
Q4 2021

Feb 10, 2022

SELL
$4.6 - $6.72 $53,180 - $77,689
-11,561 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$5.58 - $7.04 $669 - $844
-120 Reduced 1.03%
11,561 $72,000
Q2 2021

Aug 06, 2021

BUY
$5.19 - $6.73 $4,577 - $5,935
882 Added 8.17%
11,681 $71,000
Q1 2021

May 10, 2021

BUY
$5.74 - $9.67 $61,986 - $104,426
10,799 New
10,799 $68,000
Q4 2020

Feb 10, 2021

SELL
$5.3 - $6.71 $56,185 - $71,132
-10,601 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$5.73 - $8.11 $5,323 - $7,534
-929 Reduced 8.06%
10,601 $62,000
Q2 2020

Aug 10, 2020

BUY
$4.35 - $8.08 $7,847 - $14,576
1,804 Added 18.55%
11,530 $83,000
Q1 2020

May 21, 2020

BUY
$3.45 - $7.95 $33,554 - $77,321
9,726 New
9,726 $44,000
Q2 2019

Aug 13, 2019

SELL
$7.67 - $10.63 $167,574 - $232,244
-21,848 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$7.16 - $16.21 $14,405 - $32,614
2,012 Added 10.14%
21,848 $167,000
Q3 2018

Nov 09, 2018

BUY
$9.7 - $19.65 $192,409 - $389,777
19,836 New
19,836 $344,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.